OTTAWA, April 28 /CNW/ - The following is a statement by Russell Williams, President of Canada's Research-Based Pharmaceutical Companies (Rx&D), on the "Shared Vision for Perimeter Security and Economic
Competitiveness" initiative with the U.S.
"With the global economy in a still fragile state, preserving and
creating good jobs and investment in cutting edge technologies and
industries like life sciences should be a national priority.
"Our industry recognizes the importance of proceeding with a "Border
Vision" plan which includes closer cooperation between Canada and the
United States. This includes the creation of a Regulatory Cooperation
Council aimed at reducing the burden of red tape and streamlining
regulations to spark innovation and growth. This is welcome news to
businesses large and small throughout Canada.
"Harmonizing regulations to reflect modern science and sharing best
practices between Canada, the U.S. and other developed countries will
reap huge benefits for Canadian patients.
"Regulatory delays don't make prescription medicines any safer and mean
that patients may be denied the right to choose new treatment that will
benefit them. By reducing unnecessary delays, we will be able to ensure
patients have access to the right medication at the right time while
also improving patient safety.
"New medicines and vaccines reduce workplace disability and save on
health care costs for surgery, hospitalization and doctor visits. They
also help in the fight against chronic disease which costs our health
care system about $150 billion a year.
"Canada must take steps to strengthen intellectual property rights,
reduce red tape and provide access to new treatments if we want to lead
the world in attracting jobs and investment.
"We encourage all efforts that will bring much needed jobs and
sustainable growth to Canada especially in the strategically important
life sciences sector."
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information:
Mike Murphy, Communications